 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Integrated but Separate: Myriad Combines Comprehensive, BART BRCA Analysis; Pricing Remains Split
November 07, 2012
Integrated but Separate: Myriad Combines Comprehensive, BART BRCA Analysis; Pricing Remains Split
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Continuing Revenue Growth in Third Quarter, Myriad Keeps Focus on Diversifying MDx Product Portfolio
May 8, 2013 / Pharmacogenomics Reporter - Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing MDx Pipeline
August 10, 2011 / Pharmacogenomics Reporter - Myriad Expects BRACAnalysis to Remain Best Seller in 'Post-Patent' Era
February 6, 2013 / Pharmacogenomics Reporter - Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base
May 2, 2012 / Pharmacogenomics Reporter - Myriad Reports 20 Percent Q1 Revenue Growth, Rising Demand for Colorectal Cancer Test
November 2, 2011 / Pharmacogenomics Reporter